MarginsXMarginsX
Home › Markets › Health Care › ELVN

Enliven Therapeutics Inc. (ELVN)

ELVN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$47.62
-2.42% on the day
Market cap
$3.5B
Mid cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerELVN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001672619
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
27.5 months
$151.7M cash at September 30, 2026
Share count, 1 year
+24.0%
2025-10-31 to 2026-10-28 · +78.6% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$76.5M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$151.7M cash; operating cash flow -$16.6M a quarter.Report 2026-09-30
Shares outstanding73,595,132 (2026-10-28); 59,347,317 a year earlier; 41,211,973 three years earlier.Cover page 2026-10-28
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedownsLatest 2026-06-12
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, San Francisco, California, United StatesPCAOB Form AP 2026-03-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $76.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$27.7M-$12.6M$151.7MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2026
2026-06-30
Not filed-$32.5M-$18.5M$135.5MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2026
2026-03-31
Not filed-$23.6M-$19.3M$132.2MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2025
2025-12-31
Not filed-$29.7M-$15.8M$98.9MNo debt tagsNeeds four quarters10-K 2026-03-03
Q3 2025
2025-09-30
Not filed-$20.1M-$13.3M$101.7MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2025
2025-06-30
Not filed-$25.3M-$17.1M$119.4MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2025
2025-03-31
Not filed-$28.5M-$24.1M$101.7MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2024
2024-12-31
Not filed-$23.2M-$17.2M$124.1MNo debt tagsNeeds four quarters10-K 2026-03-03

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-06-12
Latest annual report10-K2026-03-03
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-27

Source: SEC EDGAR submissions feed, 799 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.3%
1 month+23.6%
3 months-15.9%
Year to date+216.9%
1 year+140.7%
From 52-week high-20.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PBLSParabilis Medicines Inc.$28.45+0.07%$3.5B
IRONDisc Medicine Inc.$76.59-4.26%$3.5B
AMLXAmylyx Pharmaceuticals Inc.$27.80-8.22%$3.6B
ARQTArcutis Biotherapeutics Inc.$27.15-3.93%$3.4B
VKTXViking Therapeutics Inc.$26.80-8.28%$3.4B
VRDNViridian Therapeutics Inc.$29.80-3.47%$3.4B
ABCLAbCellera Biologics Inc. Common Shares$11.12-3.22%$3.6B
OGNOrganon & Co. Common Stock$13.900.00%$3.7B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier